Why this biotech offers ‘far greater potential for value creation’
An Aussie biotech company that develops personalised therapies to treat cancer says it has reached “a promising point in its...
An Aussie biotech company that develops personalised therapies to treat cancer says it has reached “a promising point in its...
Investing in biotech has become an increasingly attractive proposition for venture capitalists, but the sector can be hard to navigate...
Investing in biotech has become an increasingly attractive proposition for venture capitalists, but the sector can be hard to navigate...
The US Food and Drug Administration has granted ‘orphan drug designation’ to PTX-100 for the treatment of peripheral T-cell lymphomas,...
A key US patent for Prescient Therapeutics’ OmniCAR platform has been granted, the Australian biotech company has announced, ensuring protection...
Australian biotech company Prescient Therapeutics has publicly revealed its high-performing cell therapy enhancement platform named CellPryme-M, developed in collaboration with...
Australian biotechnology company Prescient Therapeutics will expand testing of its PTX-200 drug after another patient suffering a deadly blood cancer,...
Australian biotech company Prescient Therapeutics has ended the March quarter with a sizeable cash balance despite continued investment into research...
Australian biotechnology company Prescient Therapeutics is enrolling up to 12 new patients for the next round of trials on its...
Cancer-fighting biotech company Prescient Therapeutics has continued to hit its clinical and development milestones in the first half of the...